Cardiff Oncology Inc.

2.27-0.0200-0.87%Vol 6.31M1Y Perf -69.39%
Jun 24th, 2022 16:00 DELAYED
BID2.27 ASK2.28
Open2.31 Previous Close2.29
Pre-Market- After-Market2.19
 - -  -0.08 -3.52%
Target Price
11.75 
Analyst Rating
Strong Buy 1.00
Potential %
417.62 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     59.55
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     56.38
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
15.30 
Earnings Rating
Market Cap98.30M 
Earnings Date
4th Aug 2022
Alpha-0.02 Standard Deviation0.35
Beta2.03 

Today's Price Range

2.142.57

52W Range

1.138.58

5 Year PE Ratio Range

-4.10-0.6000

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
34.32%
1 Month
94.02%
3 Months
-10.28%
6 Months
-64.81%
1 Year
-69.39%
3 Years
-8.47%
5 Years
-97.23%
10 Years
-99.18%

TickerPriceChg.Chg.%
CRDF2.27-0.0200-0.87
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
19.50
20.40
0.02
0.02
-17 679.10
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-9 397.00
-9 296.40
-5 672.70
-
RevenueValueIndustryS&P 500US Markets
361.00K
0.01
-7.04
-2.84
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.23-0.25-8.70
Q04 2021-0.17-0.23-35.29
Q03 2021-0.17-0.170.00
Q02 2021-0.15-0.17-13.33
Q01 2021-0.14-0.140.00
Q04 2020-0.15-0.19-26.67
Q03 2020-0.20-0.195.00
Q02 2020--0.51-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.25
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume6.31M
Shares Outstanding43.31K
Shares Float42.63M
Trades Count14.83K
Dollar Volume14.53M
Avg. Volume1.05M
Avg. Weekly Volume1.12M
Avg. Monthly Volume1.21M
Avg. Quarterly Volume817.44K

Cardiff Oncology Inc. (NASDAQ: CRDF) stock closed at 2.27 per share at the end of the most recent trading day (a -0.87% change compared to the prior day closing price) with a volume of 6.31M shares and market capitalization of 98.30M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cardiff Oncology Inc. CEO is Mark Erlander.

The one-year performance of Cardiff Oncology Inc. stock is -69.39%, while year-to-date (YTD) performance is -62.23%. CRDF stock has a five-year performance of -97.23%. Its 52-week range is between 1.13 and 8.58, which gives CRDF stock a 52-week price range ratio of 15.30%

Cardiff Oncology Inc. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 0.56, a price-to-sale (PS) ratio of 202.74, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.40%, a ROC of -26.65% and a ROE of -26.78%. The company’s profit margin is -%, its EBITDA margin is -9 296.40%, and its revenue ttm is $361.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Cardiff Oncology Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. Cardiff Oncology Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Cardiff Oncology Inc. is Strong Buy (1), with a target price of $11.75, which is +417.62% compared to the current price. The earnings rating for Cardiff Oncology Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cardiff Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cardiff Oncology Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 49.93, ATR14 : 0.25, CCI20 : 167.57, Chaikin Money Flow : 0.22, MACD : 0.15, Money Flow Index : 80.83, ROC : 33.53, RSI : 66.56, STOCH (14,3) : 76.00, STOCH RSI : 0.96, UO : 56.35, Williams %R : -24.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cardiff Oncology Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

CEO: Mark Erlander

Telephone: +1 858 952-7570

Address: 11055 Flintkote Avenue, San Diego 92121, CA, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

51%49%

Bearish Bullish

54%46%

News

Stocktwits